| Assessment Status | Rapid Review Complete |
| HTA ID | 24015 |
| Drug | Capivasertib |
| Brand | Truqap® |
| Indication | Capivasertib (Truqap®) is indicated in combination with fulvestrant for the treatment of adult patients with oestrogen receptor (ER)-positive, HER2-negative locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations following recurrence or progression on or after an endocrine-based regimen. |
| Assessment Process | |
| Rapid review commissioned | 30/04/2024 |
| Rapid review completed | 29/05/2024 |
| Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of capivasertib in combination with fulvestrant compared with the current standard of care. |
